WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555175
CAS#: 2199-87-3
Description: UBP608 is NMDA receptor family allosteric modulator that selectively inhibits GluN1/GluN2A receptors with a 23-fold selectivity compared to GluN1/GluN2D receptors.
Hodoodo Cat#: H555175
Name: UBP608
CAS#: 2199-87-3
Chemical Formula: C10H5BrO4
Exact Mass: 267.94
Molecular Weight: 269.050
Elemental Analysis: C, 44.64; H, 1.87; Br, 29.70; O, 23.79
Synonym: UBP608; UBP-608; UBP 608.
IUPAC/Chemical Name: 6-Bromo-2-oxo-2H-chromene-3-carboxylic acid
InChi Key: XFQHPAXNKDYMOX-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H5BrO4/c11-6-1-2-8-5(3-6)4-7(9(12)13)10(14)15-8/h1-4H,(H,12,13)
SMILES Code: O=C(C(C1=O)=CC2=C(O1)C=CC(Br)=C2)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 269.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Monaghan DT, Irvine MW, Costa BM, Fang G, Jane DE. Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int. 2012 Sep;61(4):581-92. doi: 10.1016/j.neuint.2012.01.004. Epub 2012 Jan 17. Review. PubMed PMID: 22269804; PubMed Central PMCID: PMC3360989.
2: Irvine MW, Costa BM, Volianskis A, Fang G, Ceolin L, Collingridge GL, Monaghan DT, Jane DE. Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors. Neurochem Int. 2012 Sep;61(4):593-600. doi: 10.1016/j.neuint.2011.12.020. Epub 2012 Jan 13. PubMed PMID: 22265875; PubMed Central PMCID: PMC3394894.
3: Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Laube B, Jane DE, Monaghan DT. Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid. Neuropharmacology. 2012 Mar;62(4):1730-6. doi: 10.1016/j.neuropharm.2011.11.019. Epub 2011 Dec 6. PubMed PMID: 22155206; PubMed Central PMCID: PMC3269548.
4: Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, Jane DE, Monaghan DT. A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther. 2010 Dec;335(3):614-21. doi: 10.1124/jpet.110.174144. Epub 2010 Sep 21. PubMed PMID: 20858708; PubMed Central PMCID: PMC2993558.